Quest Diagnostics 2012 Annual Report Download - page 24

21
Catherine T. Doherty (50) is Senior Vice President, Clinical Franchises. She is responsible for overseeing the
development of service offerings in the areas of cardiovascular, infectious disease, neurology, prescription drugs monitoring,
women's' health and general wellness. She also is responsible for the Care 360 connectivity program. From May 2011 to
January 2013, she served as Senior Vice President, Physician services. From 2008 through May 2011 Ms. Doherty served as
Vice President, Hospital Services. Prior to 2008, Ms. Doherty held a variety of positions of increasing responsibility since
joining the Company in 1990, including Vice President, Office of the Chairman; Vice President, Finance and Administration for
the Hospital business; Vice President, Investor Relations; and Chief Accounting Officer.
Robert A. Hagemann (56) is Senior Vice President and Chief Financial Officer. He joined Corning Life Sciences, Inc.
in 1992, where he held a variety of senior financial positions before being named Vice President and Corporate Controller of
the Company in 1996. Mr. Hagemann has served as Chief Financial Officer since August 1998. Prior to joining the Company,
he was employed by Prime Hospitality, Inc. and Crompton and Knowles in senior financial positions, and was associated with
Ernst & Young. He is a director of Zimmer Holdings, Inc.
John B. Haydon (51) is Senior Vice President, Operations. Mr. Haydon is responsible for operations for the
Company's Diagnostic Information Services business. He joined the Company in October 2012. Prior to joining Quest
Diagnostics, from May 2009 until October 2012, Mr. Haydon was employed by Royal Philips Electronics, serving as Executive
Vice President and Group Head of Global Operations and Business Excellence, and by Philips Healthcare, where he served as
Executive Vice President and Chief Supply Officer. From February 2009 to April 2009, Mr. Haydon was President and Chief
Executive Officer of Global Point Consulting, a global supply chain consulting company. From January 2008 until June 2008,
he served as Senior Vice President, Global Operations, and from July 2008 until February 2009, President and Chief Operating
Officer, of BTI Systems, an optical networking company. From September 2007 to November 2007, Mr. Haydon was
President and Chief Operating Officer of BreconRidge Manufacturing Corporation, an electronics manufacturing services
company. Previously, Mr. Haydon worked for Nortel Networks and Northern Telecom for 25 years in roles of increasing
responsibility, including with significant focus on operations and supply chain management globally.
Kathy Ordoñez (62) is Senior Vice President, Diagnostic Solutions. In this role, Ms. Ordoñez has responsibility for
the Company's Diagnostic Solutions businesses, including diagnostic products, life insurer services, clinical trials and
healthcare information technology products. Ms. Ordoñez also has responsibility in the Company's Diagnostic Information
Services business for drugs of abuse testing. From the time she joined the Company as part of its acquisition of Celera in May
2011 until January 2013, Ms. Ordoñez was responsible for managing the Company's innovation pipeline and diagnostic
products businesses, for leading Celera, including Berkeley HeartLab, and for driving the Company's focus on personalizing
disease management through diagnostic products and services. Ms. Ordoñez served as Chief Executive Officer of Celera and
was a founder of Celera Diagnostics. Prior to joining Celera's parent company, Applera, in December 2000, Ms. Ordoñez held a
number of senior positions over a 15-year period with Hoffmann La-Roche. She oversaw the formation of Roche Molecular
Systems, serving as President and Chief Executive Officer, and led the application of polymerase chain reaction technology to
the diagnostic, research and forensic fields.
Michael E. Prevoznik (51) is Senior Vice President and General Counsel. Mr. Prevoznik joined the Company as Vice
President and General Counsel in August 1999. In 2003, he assumed responsibility for governmental affairs. From 1999 until
April 2009, Mr. Prevoznik also had responsibility for the Company's Compliance Department. Since April 2011, in addition to
serving as General Counsel, Mr. Prevoznik has had management responsibility for the Company's diagnostic information
services activities outside the U.S. In addition, from April 2011 to January 2013, Mr. Prevoznik had management responsibility
for the Company's clinical trials business. Prior to joining the Company, Mr. Prevoznik served in positions of increasing
responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with
responsibility for coordinating all SmithKline Beecham compliance activities worldwide.
Item 1A. Risk Factors
You should carefully consider all of the information set forth in this Report, including the following risk factors,
before deciding to invest in any of our securities. The risks below are not the only ones that we face. Additional risks not
presently known to us, or that we presently deem immaterial, may also negatively impact us. Our business, financial condition,
results of operations or cash flows could be materially impacted by any of these factors.
This Report also includes forward-looking statements that involve risks or uncertainties. Our results could differ
materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face
described below and elsewhere. See “Cautionary Factors that May Affect Future Results” on page 31.